News

  1. Kindeva® Commemorates 70 Years Of The pMDI As Inventors Are Inducted Into The 'National Inventors Hall Of Fame' 3/26/2026
  2. BD Announces $110 Million To Support U.S. Pharmaceutical Supply Chain For Biologic Drugs 3/16/2026

    BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a $110 million investment to expand its production of prefillable syringes, helping accelerate biologic and GLP-1 drug delivery and supporting pharmaceutical reshoring in the U.S.

  3. BD And Ypsomed Expand Partnership To Address Rapidly Growing Biologics Market 3/16/2026

    BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Ypsomed, a leading developer of injection systems, are strengthening their collaboration with the development of a 5.5 mL version of the BD Neopak™ XtraFlow™ Glass Prefillable Syringe.

  4. Lifecore Biomedical Signs New Agreement With Indomo To Support Innovative Drug/Device Combination Acne Treatment 3/4/2026

    Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), and Indomo, a clinical-stage company dedicated to expanding access to quality healthcare via innovative device-enabled therapeutics, today announced that the companies have entered into a new development services agreement through which Lifecore will provide Indomo with a range of CDMO services to support the continued development of its corticosteroid drug candidate, DT-001.

  5. Subcutaneously Administered Nanotrastuzumab Matches Performance Of Herceptin HYLECTA In Minipig Study 2/12/2026

    Nanoform Finland Plc, the medicine performance-enhancing company, announced the results from a preclinical study designed to compare the tolerability and pharmacokinetics of Nanotratsuzumab, a nanoformed, novel, hyaluronidase-free, non-aqueous nanoparticle suspension of trastuzumab for subcutaneous delivery versus Herceptin HYLECTA™, a co-formulated product with Halozyme’s proprietary hyaluronidase enzyme marketed by Roche/Genentech.

  6. Kindeva Announces Leadership Transition To Drive Strategic Growth 1/16/2026

    Kindeva, a global contract development and manufacturing organization (CDMO) and drug delivery innovator, today announced a series of planned leadership transitions designed to position the company for accelerating growth in its core businesses focused on parenteral and inhaled drug delivery. 

  7. AbbVie To Buy Device Manufacturing Facility From West Pharmaceutical Services 1/14/2026

    The acquisition of the Tempe, Arizona facility will expand U.S.-based drug delivery device capacity and support the company’s $10 billion manufacturing investment.

  8. Halozyme Completes Acquisition Of Elektrofi, Expanding Breadth Of Offerings In Drug Delivery 11/20/2025

    Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the successful completion of its acquisition of Elektrofi, Inc. ("Elektrofi"), a biopharmaceutical company with a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon™

  9. Owen Mumford Launches EcoSafe® Safety Syringe Platform – Smarter For Budgets And Kinder To The Planet 10/29/2025

    Oxford - Medical device expert Owen Mumford has extended its 1ml safety syringe platform by adding a companion reusable autoinjector.

  10. Ensera Launches As New Brand Identity For SteriPack 10/14/2025

    New trading name reflects expanded expertise across design, manufacturing, assembly and packing for global pharma and medical device companies.